| Annual · values | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -38.53 M USD | -60.88 M USD | -82.24 M USD | -80.11 M USD | -69.92 M USD | 9.37 M USD |
| Depreciation & Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — |
| Capital Expenditures | — | — | — | — | — | — |
| Cash Flow from Investing | — | — | — | — | — | — |
| Cash Flow from Financing | — | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — | — |
| Stock Buybacks | — | — | — | — | — | — |
| Free Cash Flow | -43.74 M USD | -66.45 M USD | -84.37 M USD | -78.75 M USD | -65.06 M USD | 12.52 M USD |
Calithera Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule compounds, primarily in the field of tumor biology. Its primary function involves discovering and advancing therapeutic candidates that can potentially address various cancer-related challenges. The company operates within the biotechnology sector, specifically targeting precision oncology. Although it has transitioned into a plan of liquidation, historically, Calithera Biosciences Inc. contributed to advancements in cancer treatment through innovative small molecule therapies. Headquartered in South San Francisco, California, the company was founded in 2010 and played a role in shaping the landscape of cancer research.